Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.86 |
| ▸ | MAPT | P10636 | 2/20 | 0.86 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.86 |
| ▸ | HTT | P42858 | 1/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.60 |
| ▸ | KLK7 | P49862 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14962804 | 0.90 | HPGD (0.81) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL6746325 | 0.87 | MAPT (0.68) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL9495103 | 0.86 | SMN1; SMN2 (0.71) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL4696809 | 0.84 | NAMPT (0.65) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL9125307 | 0.83 | ALDH1A1 (0.65) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL5009752 | 0.83 | HPGD (0.68) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL1976948 | 0.82 | HPGD (0.71) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL22854085 | 0.82 | HPGD (0.71) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL11718184 | 0.82 | ALOX5 (0.62) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL764569 | 0.82 | HPGD (0.71) | HPGDMAPTALOX12MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116829730-A | Chromatin occupancy and single cell analytical sequencing of RNA | 美国政府卫生与公众服务部 | 2023-09-29 | — | — | CN | claimed |
| CN-114736532-A | High-speed high-tinting-strength and peculiar-smell-free pigment yellow synthesis method | 浙江科隆颜料科技有限公司 | 2022-07-12 | — | — | CN | claimed |
| EP-2629889-B1 | RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RES & DEV (IL) | 2019-04-03 | — | — | EP | claimed |
| US-20170283447-A1 | RUTHENIUM COMPLEXES AND THEIR USES AS CATALYSTS IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND RELATED REACTIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-10-05 | — | — | US | claimed |
| EP-3188832-A1 | RUTHENIUM COMPLEXES AND THEIR USES AS CATALYSTS IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND RELATED REACTIONS | Yeda Research and Development Co., Ltd. (IL) | 2017-07-12 | — | — | EP | claimed |
| US-9290441-B2 | Use of ruthenium complexes for formation and/or hydrogenation of amides and related carboxylic acid derivatives | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-03-22 | — | — | US | claimed |
| WO-2016035080-A1 | RUTHENIUM COMPLEXES AND THEIR USES AS CATALYSTS IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND RELATED REACTIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-03-10 | — | — | WO | claimed |
| EP-2629889-A2 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | Yeda Research and Development Co. Ltd. (IL) | 2013-08-28 | — | — | EP | claimed |
| US-20120253042-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-10-04 | — | — | US | claimed |
| CN-102702194-A | Anti-viral compounds | ABBOTT LAB | 2012-10-03 | — | — | CN | claimed |
| WO-2012052996-A2 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-04-26 | — | — | WO | claimed |
| US-20020156109-A1 | 1,4-dihydropyridine derivative with a guaiacoxypropanolamine and/or phenoxypropanolamine moiety | CHEN ING-JUN (TW) | 2002-10-24 | — | — | US | claimed |
| EP-1108710-A1 | GUAIACOXYPROPANOLAMINES WITH ALPHA/BETA-ADRENERGIC BLOCKING ACTIVITY | Cheng, Ing-Jun (TW) | 2001-06-20 | — | — | EP | claimed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | claimed |
| EP-0423282-B1 | PROCESS FOR PREPARING N-PHENYL-N-METHOXYACETYL-DL-ALANINE-METHYLESTER DERIVATIVES | NITRO-KEMIA IPARTELEPEK (HU) | 1993-08-04 | — | — | EP | claimed |
| EP-0423282-A1 | PROCESS FOR PREPARING N-PHENYL-N-METHOXYACETYL-DL-ALANINE-METHYLESTER DERIVATIVES. | NITRO KEMIA IPARTELEPEK (HU) | 1991-04-24 | — | — | EP | claimed |
| WO-1990012783-A1 | PROCESS FOR PREPARING N-PHENYL-N-METHOXYACETYL-DL-ALANINE-METHYLESTER DERIVATIVES | NITROKÉMIA IPARTELEPEK (HU) | 1990-11-01 | — | — | WO | claimed |
| EP-4370207-B1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-3957860-A | SULFAMIC ACID | CIBA-GEIGY AG (CH) | 1976-05-18 | — | — | US | disclosed |
| US-3951941-A | POLYAZODYE | SAKAI CHEMICAL INDUSTRY COMPANY, LIMITED (JA) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253042-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | ADH5, ADH1C, ADH1A | HPGD 524/4885MAPT 3690/4885ALOX12 2078/4885 |
| US-20020156109-A1 | 1,4-dihydropyridine derivative with a guaiacoxypropanolamine and/or phenoxypropanolamine moiety | ADRA1D, ADRA2C, ADRB3 | HPGD 936/4885MAPT 3761/4885ALOX12 1346/4885 |
| US-20170283447-A1 | RUTHENIUM COMPLEXES AND THEIR USES AS CATALYSTS IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND RELATED REACTIONS | ADH1A, ADH1C, ADH5 | HPGD 2746/4885MAPT 4155/4885ALOX12 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.